MedPath

The clinical efficacy of external application of mirabilite and rhubarb combined with intrathoracic chemotherapy in treating malignant pleural effusion: a prospective, randomized, controlled clinical trial

Phase 1
Recruiting
Conditions
malignant pleural effusion
Registration Number
ITMCTR2000003487
Lead Sponsor
onghua Hospital affiliated to Shanghai University of Chinese Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

(1) At least 1 imaging examination (X-ray, B-ultrasound) showed moderate or above malignant pleural effusion, and the time between imaging examination and inclusion was <= 2 weeks.
(2) Advanced malignant tumor with malignant pleural effusion confirmed by histopathology or cytology.
(3) The expected survival time is more than 3 months, and the age of 18 <= 80 years.
(4) Karnofsky score >= 60, ECOG PS score <= 2.
(5) No serious heart, kidney, liver diseases or other therapeutic contraindications.
(6) No chemotherapy or intrathoracic drug injection was performed within 1 month before the inclusion of treatment, except for diagnostic puncture.
(7) Sign informed consent and receive medical treatment.

Exclusion Criteria

(1) End-stage patients with cachexia and severe hypoproteinemia, unable to complete one course of treatment.
(2) Pregnant women, patients with mental disorders and those who do not cooperate with treatment.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
QLQ C30 scale;
Secondary Outcome Measures
NameTimeMethod
TCM syndrome score;Safety index;
© Copyright 2025. All Rights Reserved by MedPath